The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past decade. Liquid biopsy is a rapidly emerging field to address this unmet clinical need as diagnostics based on cell-free circulating tumor DNA (ctDNA) can be a surrogate for the entire tumor genome.
We have developed a liquid biopsy technology “Electric Field Induced Release and Measurement (EFIRM)- Liquid Biopsy (eLB)” which provides the most accurate targeted detection that can assist clinical treatment decisions for the most common subtype of lung cancer, non-small cell lung cancer (NSCLC), where tyrosine kinase inhibitors (TKI) can extend the disease progress free survival period of these patients.
Attend this webinar to learn about:
The role of liquid biopsy in cancer detection
Electric field induced released and measurement (EFIRM), a novel liquid biopsy technology
The use and benefits of saliva as a sample type for liquid biopsy
David Wong Director
Center for Oral/Head & Neck Oncology Research
Technology Networks Limited
Woodview | Bull Lane Industrial Estate | Sudbury | C010 0FD | UK